The Prosigna genomic test may help identify breast cancer patients who are likely to gain little benefit from chemotherapy ...
A new DNA test could spare millions of breast cancer patients from chemotherapy. We answer your questions about what it means ...
A new genetic test could help many women with breast cancer safely skip chemotherapy, reducing side effects while ensuring ...
THOUSANDS of women with breast cancer could avoid chemotherapy without risking their survival chances thanks to a new gene ...
inews.co.uk on MSN
Breast cancer breakthrough: many women to be spared from chemotherapy
As many as 5,000 women a year with hormone-sensitive breast cancer could benefit ...
Women are more likely to survive cancer than men but face a higher risk of serious and adverse side effects from treatment, according to a landmark international study from Adelaide University.
Morning Overview on MSN
A new genomic test could spare two-thirds of high-risk breast cancer patients from chemotherapy entirely, per ASCO 2026 results
Thousands of women diagnosed with high-risk, estrogen-receptor-positive breast cancer may no longer need chemotherapy, ...
A groundbreaking international trial, Optima, reveals a genomic test, Prosigna, can identify breast cancer patients unlikely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results